Encompass Health (NYSE:EHC) had its target price raised by stock analysts at Craig Hallum from $63.00 to $71.00 in a research report issued to clients and investors on Monday, Stock Target Advisor reports. The brokerage presently has a “buy” rating on the stock. Craig Hallum’s price objective would suggest a potential upside of 17.49% from the company’s previous close.
A number of other brokerages have also recently commented on EHC. ValuEngine upgraded shares of Encompass Health from a “buy” rating to a “strong-buy” rating in a research note on Friday. Credit Suisse Group upped their price target on shares of Encompass Health from $65.00 to $66.00 and gave the company an “outperform” rating in a research note on Friday. SunTrust Banks reiterated a “buy” rating and issued a $70.00 target price on shares of Encompass Health in a research note on Tuesday, April 17th. Mizuho initiated coverage on shares of Encompass Health in a research note on Thursday, March 29th. They issued a “buy” rating and a $62.00 target price on the stock. Finally, Piper Jaffray reiterated a “hold” rating on shares of Encompass Health in a research note on Thursday, March 1st. Two analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $67.33.
Shares of EHC stock traded down $0.39 during trading on Monday, reaching $60.43. 108,904 shares of the company’s stock traded hands, compared to its average volume of 607,122. The stock has a market capitalization of $6,039.48, a P/E ratio of 21.92, a PEG ratio of 1.39 and a beta of 0.38. The company has a current ratio of 1.24, a quick ratio of 1.36 and a debt-to-equity ratio of 1.77. Encompass Health has a 1 year low of $42.21 and a 1 year high of $62.54.
Encompass Health (NYSE:EHC) last announced its quarterly earnings results on Monday, February 26th. The company reported $0.70 EPS for the quarter, beating the Zacks’ consensus estimate of $0.66 by $0.04. The company had revenue of $1.02 billion for the quarter, compared to analysts’ expectations of $1 billion. Encompass Health had a net margin of 6.76% and a return on equity of 20.76%. equities analysts predict that Encompass Health will post 3.37 EPS for the current year.
About Encompass Health
Encompass Health Corporation provides facility-based and home-based post-acute healthcare services in the United States. The company operates through two segments, Inpatient Rehabilitation, and Home Health and Hospice. The Inpatient Rehabilitation segment provides specialized rehabilitative treatment on an inpatient and outpatient basis to patients who are recovering from conditions, such as stroke and other neurological disorders, cardiac and pulmonary conditions, brain and spinal cord injuries, complex orthopedic conditions, and amputations.
Receive News & Ratings for Encompass Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Encompass Health and related companies with MarketBeat.com's FREE daily email newsletter.